InvestorsHub Logo
Followers 33
Posts 2841
Boards Moderated 2
Alias Born 10/24/2015

Re: None

Wednesday, 10/05/2022 3:35:27 PM

Wednesday, October 05, 2022 3:35:27 PM

Post# of 265
SITC titles

CTX130 allogeneic CRISPR-Cas9–engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Results from the Phase 1 COBALT-RCC study

CRISPR/Cas9 gene-edited, allogeneic anti-CD83 CAR-T cells demonstrate potent activity in GvHD and AML tumor models
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CRSP News